|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
It is suggested that the GSTT1 polymorphism may have an impact on the severity of the tumor and its location.
|
30106268 |
2018 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Thus, logistic regression analysis adjusted by tumor size revealed a positive association between GSTT1 deletion and recurrence risk in general BC (OR 4.25; p = 0.04), while GSTM1 was negatively associated with recurrence risk in ER/PR<sup>+</sup>HER2<sup>-</sup> samples (OR 0.07; p = 0.03).
|
28455582 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This meta-analysis suggests that GSTM1 null and GSTT1/GSTM1 double null polymorphisms might be significantly associated with an increased tumor response.
|
26577857 |
2016 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
With great interest, we read the paper "GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis" (by Hu XY et al.), which has reached important conclusions that GSTM1 null and GSTT1/GSTM1 double null polymorphisms might be significantly associated with an increased tumor response in breast cancer.The result is encouraging.
|
27444273 |
2016 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We studied the association between tumor pathology and the expression profile of seven phase I and II drug metabolizing genes (CYP1A1, CYP1B1, ALDH3A1, AOX1, GSTP1, GSTT1 and GSTM3) and some of their proteins.
|
26580399 |
2015 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Human health effects of dichloromethane: key findings and scientific issues.
|
25325283 |
2015 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Epidemiological studies have suggested that individuals with homozygous deletion of glutathione S-transferase mu 1 (GSTM1) and glutathione S-transferase theta 1 (GSTT1) are at higher risk of developing several types of neoplasias.
|
26782376 |
2015 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
After stratification based on the tumor stage and grade, the high-risk group (T1G3) with a GSTT1-positive genotype showed a 14-fold higher risk of early BCG failure compared with those with a GSTT1-null genotype.
|
24411789 |
2014 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Moreover, GSTT1 expression retarded xenograft tumor formation of Hydroquinone-treated lymphoma cells in nude mice.
|
24586676 |
2014 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A significantly lower frequency of GSTT1 deletion in glioma patients compared to healthy controls indicates that GSTT1 deletion may exert a protective role against gliomagenesis, influence therapeutic response to intranasal perillyl alcohol treatment, and increase overall survival, especially considering tumor topography.
|
23765968 |
2013 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Here, we have investigated the association of tobacco - betel quid chewing, HPV infection, GSTM1-GSTT1 null genotypes, and tumour stages with mitochondrial DNA (mtDNA) content variation in oral cancer patients.
|
23469236 |
2013 |
|
Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Here, we studied the interaction of various habits related factors and polymorphism of GSTM1/GSTT1 genes towards inducing promoter hypermethylation of multiple tumour suppressor genes.
|
23596512 |
2013 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Patients with GSTT1 deletion had tumors of more advanced stages, and those with Val432 polymorphism in CYP1B1 had tumors of higher Fuhrman grade.
|
21458313 |
2013 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In this study we investigate the association of A313G and C341T GSTP1 polymorphisms, GSTM1 and GSTT1 null genotypes in the head and neck cancer development, interactions between these polymorphisms,the tumor histopathologic parameters and risk factors (smoking and drinking) were also evaluated in the case-control study.
|
23661016 |
2013 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
GSTT1 mRNA expression was higher in muscle-invasive BC and high-grade cancers than in non-muscle-invasive BC and lower-grade tumors.
|
21079384 |
2011 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
GSTM1 and GSTT1 expression was also downregulated in stage wise pattern; stage 1 had 50% and 12.5% tissues showing down regulation of GSTM1 and GSTT1 genes respectively, both GSTM1 and GSTT1 had 55% tissues with down regulation in stage 2, similarly stage 3 had 60% tissues showing down regulation of these genes and stage 4 had 86% and 71% tumors.
|
21545198 |
2011 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In GSTM1-GSTT1 interaction analysis, individuals with dual null genotype were associated with a significantly increased risk of cervical neoplasia (OR = 1.72; 95%CI, 1.18-2.51).
|
21629772 |
2011 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Among the patients with oligodendroglial tumors (n = 94), patients who had the GSTT1 null genotype had a 2.9 times increased risk of death (95% confidence interval [CI], 1.3-6.3) compared with patients who had the GSTT1 non-null genotype.
|
20187096 |
2010 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Concerning overall survival, lower tumor stage (p = 0.006) and International Prognostic Score (p = 0.02), lower peripheral leukocyte count (p = 0.0003), higher serum albumin level (p = 0.08), and GSTT1 undeleted genotype (p = 0.04) were predictive of a better outcome of patients.
|
20977336 |
2010 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Furthermore, NAT2 slow-acetylator, GSTM1 null, and GSTM1/GSTT1-double null genotypes were associated with higher tumor grade (P=0.001, 0.022, and 0.036, respectively), and only NAT2 slow-acetylator genotype was associated with higher tumor stage (P=0.007).
|
19303722 |
2009 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tumor tissue (n=197) was later retrieved from hospital of diagnosis and assayed using multiplex PCR (GSTM1 and GSTT1) and PCR and RFLP analysis (GSTP1).
|
19748847 |
2009 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We found that African-Americans with the GSTT1 null genotype had increased BCR risk compared to those having GSTT1 present (hazard ratio (HR) = 2.30; 95% CI = 1.01–5.18; p = 0.04); and African-Americans with the GSTT1 null genotype and high grade tumors had an even greater risk (HR = 7.82; 95% CI = 2.49–24.50; p < 0.001).
|
19568698 |
2009 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A case control association study was carried out to investigate polymorphisms in genes CYP1A1 (3801T > C), GSTM1, and GSTT1 (null genotypes) and oral squamous cell carcinoma (OSCC), including a correlation with some histopathological findings (tumor size, lymph node invasion and degree of tumor differentiation).
|
18507050 |
2008 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Both GSTM1*0 (16/26 (61%) versus 10/40 (25%); p=0.003, OR 5; 95% CI=2-14) and GSTT1*0 (12/26 (46%) versus 13/40 (33%); p=0.2, OR 2; 95% CI=0.6-5) were associated with a higher risk of diffuse tumor than of intestinal tumor.
|
18365908 |
2008 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Using restriction fragment length polymorphism (RFLP) analysis, we have examined a cohort of 597 French VC workers for polymorphisms in CYP2E1, ALDH2, GSTM1 and GSTT1 in relation to the occurrence of mutant oncogene and tumor suppressor gene biomarkers that are attributable to VC exposure.
|
17384900 |
2007 |